Drugmakers sue Trump over prices in TV ads

Amgen, Eli Lilly and MSD have sued the Trump administration to try and block measures to force pharma companies to include prices in TV ads.
Three of America’s biggest drugmakers filed a lawsuit against the Trump administration over the Department of Health and Human Services (HHS) ruling to force pharmaceutical companies to list the prices of their drugs in adverts on TV.
Amgen, Merck and Eli Lilly have said the HHS does not have the legal power to force drugmakers to include prices and that the measure would cause confusion for patients.
“Americans deserve accurate information about the price they will pay for prescription drugs,” the lawsuit says.
“This case involves a rule adopted by the Department of Health and Human Services (HHS) that purports to further that objective, but will instead frustrate it—by misleading patients about their out-of-pocket costs for prescription drugs in a manner that even HHS admits may “confuse” and “intimidate” patients, “discourage patients from using beneficial medications, reduce access, and potentially increase total cost of care.”
Amgen commented in a statement: “Not only does the rule raise serious freedom of speech concerns, it mandates an approach that fails to account for differences among insurance, treatments, and patients themselves, by requiring disclosure of list price.”
Louis Goss
- Login or register to post comments
- Printer-friendly version
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches
Related content
- US Judge blocks Trump administration law requiring pharma to include prices in TV ads
- NICE rejects Merck Serono’s Bavencio for urothelial cancer
- Merck kidney and uterus cancer treatments granted priority review by FDA
- Merck cease development of $425 million COVID-19 treatment
- HHS to fund production of MSD's Ebola vaccine V920